The Metabolic Functional Feature of Gut Microbiota in Mongolian Patients with Type 2 Diabetes
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The accumulating evidence substantiates the indispensable role of gut microbiota in modulating the pathogenesis of type 2 diabetes. Uncovering the intricacies of the mechanism is imperative in aiding disease control efforts. Revealing key bacterial species, their metabolites and/or metabolic pathways from the vast array of gut microorganisms can significantly contribute to precise treatment of the disease. With a high prevalence of type 2 diabetes in Inner Mongolia, China, we recruited volunteers from among the Mongolian population to investigate the relationship between gut microbiota and the disease. Fecal samples were collected from the Volunteers of Mongolia with Type 2 Diabetes group and a Control group, and detected by metagenomic analysis and untargeted metabolomics analysis. The findings suggest that Firmicutes and Bacteroidetes phyla are the predominant gut microorganisms that exert significant influence on the pathogenesis of type 2 diabetes in the Mongolian population. In the disease group, despite an increase in the quantity of most gut microbial metabolic enzymes, there was a concomitant weakening of gut metabolic function, suggesting that the gut microbiota may be in a compensatory state during the disease stage. β-Tocotrienol may serve as a pivotal gut metabolite produced by gut microorganisms and a potential biomarker for type 2 diabetes. The metabolic biosynthesis pathways of ubiquinone and other terpenoid quinones could be the crucial mechanism through which the gut microbiota regulates type 2 diabetes. Additionally, certain Clostridium gut species may play a pivotal role in the progression of the disease.
Abstract
The accumulating evidence substantiates the indispensable role of gut microbiota in modulating the pathogenesis of type 2 diabetes. Uncovering the intricacies of the mechanism is imperative in aiding disease control efforts. Revealing key bacterial species, their metabolites and/or metabolic pathways from the vast array of gut microorganisms can significantly contribute to precise treatment of the disease. With a high prevalence of type 2 diabetes in Inner Mongolia, China, we recruited volunteers from among the Mongolian population to investigate the relationship between gut microbiota and the disease. Fecal samples were collected from the Volunteers of Mongolia with Type 2 Diabetes group and a Control group, and detected by metagenomic analysis and untargeted metabolomics analysis. The findings suggest that Firmicutes and Bacteroidetes phyla are the predominant gut microorganisms that exert significant influence on the pathogenesis of type 2 diabetes in the Mongolian population. In the disease group, despite an increase in the quantity of most gut microbial metabolic enzymes, there was a concomitant weakening of gut metabolic function, suggesting that the gut microbiota may be in a compensatory state during the disease stage. β-Tocotrienol may serve as a pivotal gut metabolite produced by gut microorganisms and a potential biomarker for type 2 diabetes. The metabolic biosynthesis pathways of ubiquinone and other terpenoid quinones could be the crucial mechanism through which the gut microbiota regulates type 2 diabetes. Additionally, certain Clostridium gut species may play a pivotal role in the progression of the disease.
참고문헌 (27)
- Chaudhari SN, "Chains of evidence from correlations to causal molecules in microbiome-linked diseases", Nat. Chem. Biol, 17, pp.1046~1056 (2021)
- Li Y, "Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association : national cross sectional study", BMJ, 369, pp.m997~ (2020)
- Duan M, "Prevalence, awareness, treatment and control of type 2 diabetes and its determinants among Mongolians in China : a cross-sectional analysis of IMAGINS 2015-2020", BMJ Open, 12, pp.e063893~ (2022)
- Zhou Z, "Gut microbiota : an important player in type 2 diabetes mellitus", Front. Cell. Infect. Microbiol, 12, pp.834485~ (2022)
- Wu H, "The gut microbiota in prediabetes and diabetes : a population-based cross-sectional study", Cell Metab, 32, pp.379~390 (2020)
- Human Microbiome Project Consortium, "Structure, function and diversity of the healthy human microbiome", Nature, 486, pp.207~214 (2012)
- Sharma S, "Gut microbiome and type 2 diabetes : where we are and where to go?", J. Nutr. Biochem, 63, pp.101~108 (2019)
- Zhu T, "Metabolites linking the gut microbiome with risk for type 2 diabetes", Curr. Nutr. Rep, 9, pp.83~93 (2020)
- Liu Y, "Differences in gut microbiota and its metabolic function among different fasting plasma glucose groups in Mongolian population of China", BMC Microbiol, 23, pp.102~ (2023)
- Yu G, "MetOrigin : discriminating the origins of microbial metabolites for integrative analysis of the gut microbiome and metabolome", IMeta, 1, pp.e10~ (2022)
- Ringnér M, "What is principal component analysis?", Nat. Biotechnol, 26, pp.303~304 (2008)
- Young MP, "Non-metric multidimensional scaling in the analysis of neuroanatomical connection data and the organization of the primate cortical visual system", Philos Trans. R Soc. Lond B Biol. Sci, 348, pp.281~308 (1995)
- Segata N, "Metagenomic biomarker discovery and explanation", Genome Biol, 12, pp.R60~ (2011)
- Thévenot EA, "Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses", J. Proteome Res, 14, pp.3322~3335 (2015)
- Fan Y, "Gut microbiota in human metabolic health and disease", Nat. Rev. Microbiol, 19, pp.55~71 (2021)
- Krautkramer KA, "Gut microbial metabolites as multi-kingdom intermediates", Nat. Rev. Microbiol, 19, pp.77~94 (2021)
- Sun Z, "Inhibition of PD-L1-mediated tumor-promoting signaling is involved in the anti-cancer activity of β-tocotrienol", Biochem. Biophys. Res. Commun, 617(Pt 2), pp.33~40 (2022)
- Montonen J, "Dietary antioxidant intake and risk of type 2 diabetes", Diabetes Care, 27, pp.362~366 (2004)
- Harlan L, "Mechanisms mediating anti-inflammatory effects of delta-tocotrienol and tart cherry anthocyanins in 3T3-L1 adipocytes", Nutrients, 12, pp.3356~ (2020)
- Hosomi K, "Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota", Nat. Commun, 13, pp.4477~ (2022)
- Nicoletti F, "Effects of sodium fusidate in animal models of insulindependent diabetes mellitus and septic shock", Immunology, 85, pp.645~650 (1995)
- Nicoletti F, "Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin", J. Autoimmun, 15, pp.395~405 (2000)
- Conget I, "Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus : the FUSIDM trial", Diabetologia, 48, pp.1464~1468 (2005)
- Zabela V, "Single dose pharmacokinetics of intravenous 3, 4-dihydroxyphenylacetic acid and 3-hydroxyphenylacetic acid in rats", Fitoterapia, 142, pp.104526~ (2020)
- Dhanya R, "Quercetin for managing type 2 diabetes and its complications, an insight into multitarget therapy", Biomed. Pharmacother, 146, pp.112560~ (2022)
- Duncan SH, "Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product", Appl. Environ. Microbiol, 70, pp.5810~5817 (2004)
- Macfarlane S, "Composition and metabolic activities of bacterial biofilms colonizing food residues in the human gut", Appl. Environ. Microbiol, 72, pp.6204~6211 (2006)